Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1758 • ACR Convergence 2022
Intake of Dairy Products as a Risk Factor for Rheumatoid Arthritis; A Nested Case-Control Study
Camilla LIndegren¹, Emily Sonestedt¹, Emil Rydell¹, Linnea Arvidsson¹, Ulf Bergström¹ and Carl Turesson², ¹Lund University, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: There has been increasing interest in diet as a factor that may contribute to the development of rheumatoid arthritis (RA). There is limited and…
Abstract Number: 1953 • ACR Convergence 2022
Mortality in Rheumatoid Arthritis: Changing Causes and Predictive Factors. Study of a Cohort Followed Prospectively
Cristina Corrales¹, Fabricio Benavides Villanueva¹, Ivan Ferraz Amaro², Nuria Vegas Revenga³, Virgi Portilla⁴, Ricardo Blanco⁵, Miguel Ángel González-Gay⁶ and Alfonso Corrales⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³Hospital Galdakao- Usansolo, Galdakao, Spain, ⁴Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Patients with Rheumatoid Arthritis (RA) present an increased risk of mortality. In the last decades, mortality rates tended to decrease but cardiovascular (CV) events…
Abstract Number: 1970 • ACR Convergence 2022
Detecting Inflammatory Changes in Seronegative Inflammatory Arthritis with Use of Musculoskeletal Ultrasound Studies
Clarice P. Lin¹ and Richard C. Chou², ¹University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Medicine, Buffalo, NY, ²University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Division of Allergy, Immunology, & Rheumatology, Department of Medicine, Buffalo, NY
Background/Purpose: Recent clinical practice has increasingly utilized musculoskeletal (MS) ultrasound studies to assess inflammation and soft-tissue abnormalities of the joints, such as synovitis and bone…
Abstract Number: 1987 • ACR Convergence 2022
Prednisone Use and the Incidence of Hyperglycemia or Diabetes in Patients with Rheumatoid Arthritis; A 10-year Sub Analysis of the BeSt Study
CF Allaart¹, Sytske Anne Bergstra², Tom Huizinga¹ and Joy van der Pol³, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Leiden University Medical Center, Utrecht, Netherlands
Background/Purpose: Use of prednisone in rheumatoid arthritis has been questioned because it may trigger side effects such as hyperglycemia and diabetes. However, disease activity (DAS)…
Abstract Number: 2004 • ACR Convergence 2022
Which Route and Dose of Corticosteroids Is Most Effective in Inducing Remission in Early Rheumatoid Arthritis? A Systematic Literature Review and Meta-analysis
Laura Parker¹ and Nicola Gullick², ¹University of Warwick, Coventry, United Kingdom, ²University Hospital Coventry & Warwickshire; Warwick Medical School, University of Warwick, Coventry, United Kingdom
Background/Purpose: Current NICE guidance for rheumatoid arthritis (RA) states that glucocorticoids may be used for bridging therapy and to rapidly decrease inflammation in acute flares1.…
Abstract Number: 2182 • ACR Convergence 2022
mRNA Vaccine Against Fibroblast Activation Protein Ameliorates Murine Models of Inflammatory Arthritis
Xiaowei Zhang¹, Antony Jozic¹, Pingfang Song¹, Qiang Xu², Xiaofei Shi³, Hong Wang⁴, Lindsey Bishop¹, Hillary Struthers¹, John Rutledge⁵, Shuang Chen¹, Fei Xu¹, Meaghan Hancock¹, Daocheng Zhu⁶, Gaurav Sahay¹ and Cong-Qiu Chu¹, ¹Oregon Health & Science University, Portland, OR, ²Guangzhou University of Chinese Medicine, Guangzhou, China, ³Henan University of Science and Technology, Luoyang, China, ⁴Wenzhou Medical University, Wenzhou, China, ⁵Portland VA Research Foundation, Portland, ⁶Shanghai Kexin Biotechnology, Shanghai, China
Background/Purpose: Synovial fibroblasts in patients with rheumatoid arthritis (RA) contribute substantially to the perpetuation of synovitis and invasion to cartilage and bone, and have been…
Abstract Number: 2249 • ACR Convergence 2022
Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rheumatoid Arthritis: A Multicenter Comparative Study
Gabriel Figueroa Parra¹, Emily Gilbert², Maria Valenzuela Almada¹, Sebastian Vallejo¹, Matthew Neville³, Naomi Patel⁴, Claire Cook⁵, Xiaoqing Fu⁵, Ramla Hagi⁵, Gregory McDermott⁶, Michael Dilorio⁶, Lucy Masto⁶, Kathleen Vanni⁶, Emily Kowalski⁶, Grace Qian⁶, Zachary Wallace⁵, Ali Duarte-Garcia¹ and Jeffrey Sparks⁷, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Jacksonville, FL, ³Mayo Clinic, Phoenix, AZ, ⁴Massachusetts General Hospital, Sale Creek, TN, ⁵Massachusetts General Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) has been associated with severe COVID-19, but few studies have investigated outcomes in RA phenotypes such as interstitial lung disease (RA-ILD),…
Abstract Number: 0060 • ACR Convergence 2022
Lower Healthcare Costs for Commercially Insured Patients with Rheumatoid Arthritis in Remission
Jeffrey Curtis¹, Kathleen Fox², Fenglong Xie³, Yujie Su³, David Collier⁴, Cassie Clinton³ and Hafiz Oko-osi⁵, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Strategic Health (formerly with Amgen), Thousand Oaks, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Amgen Inc., Simi Valley, CA, ⁵Gilead Sciences, Foster City, CA
Background/Purpose: Rheumatoid arthritis (RA) affects about 1-2% of adults with annual US costs at $19 billion. Most studies evaluating cost of care have not had…
Abstract Number: 0118 • ACR Convergence 2022
Sex-Based Variations in Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions
Cheryl Barnabe¹, Patrick McLane², Nadia Luca¹, Katie Lin¹, Kelsey Chomistek¹, Meghan Elliott¹, Shanon McQuitty³, Eileen Davidson³, Clare Hildebrandt⁴, Steven Katz², Brian Holroyd² and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Patient and Family Advisors, Alberta Health Services, Calgary, AB, Canada
Background/Purpose: High quality ambulatory care provision should mitigate avoidable emergency department (ED) visits by persons with inflammatory arthritis (IA) conditions and address the unique realities…
Abstract Number: 0241 • ACR Convergence 2022
Inequity in Disease Impact Between Male and Female Rheumatoid Arthritis Patients
Gonul Hazal Koc¹ and Pascal de Jong², ¹Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, the Netherlands, Rotterdam, Netherlands, ²ErasmusMC, Hendrik Ido Ambacht, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is more common in females than males. Moreover, males and females may have different disease courses and burdens, but data on…
Abstract Number: 0257 • ACR Convergence 2022
High Density Lipoprotein Bound miR-1246 Is Enriched in Patients with Rheumatoid Arthritis and Is Proinflammatory
Qiong Wu, Quanhu Sheng, Danielle Michell, Kasey Vickers and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: High density lipoprotein (HDL) is known for its anti-atherogenic cholesterol efflux and antioxidant functions. HDL has additional relevance to rheumatoid arthritis (RA) because of…
Abstract Number: 0273 • ACR Convergence 2022
An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderately to Severely Active RA
Kevin Winthrop¹, Daniel Aletaha², Roberto Felice Caporali³, Yoshiya Tanaka⁴, Tsutomu Takeuchi⁵, Paul Van Hoek⁶, Christopher Watson⁷, Pieter-Jan Stiers⁶, Vijay Rajendran⁸, Katrien Van Beneden⁶, jacques-eric gottenberg⁹ and Gerd Burmester¹⁰, ¹Oregon Health & Science University, Portland, OR, ²Medical University Vienna, Wien, Austria, ³University of Milan, Milano, Italy, ⁴University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁵Keio University and Saitama Medical University, Tokyo, Japan, ⁶Galapagos NV, Mechelen, Belgium, ⁷Galapagos Biotech Ltd, Cambridge, United Kingdom, ⁸Galapagos NV, Gent, Belgium, ⁹Strasbourg University Hospital, Strasbourg, France, ¹⁰Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is a second-generation oral Janus kinase 1 preferential inhibitor approved in Europe, Japan, and the UK for treatment of RA.1,2 Over a…
Abstract Number: 0291 • ACR Convergence 2022
Tofacitinib Leads to Significant Weight Gain – A Real Life Experience of 429 Patients
Naga Prabu¹, velammal petchaippan², Gayathri anand³, Aswathi kumar¹ and Saranya Ramachandiran³, ¹SAKTHI RHEUMATOLOGY CENTRE PVT LTD, Coimbatore, India, ²PSG INSTTUTE OF MEDICAL SCIENCES AND RESEARCH, Coimbatore, India, ³sakthi rheumatology centre pvt l;td, Coimbatore, India
Background/Purpose: Tofacitinib(Tofa) an oral Janus kinase inhibitor(JAK) has shown good promise in the management of rheumatoid arthritis and psoriatic arthritis. While being increasingly used in…
Abstract Number: 0309 • ACR Convergence 2022
Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis – Results of an Open-Label Extension Study
Eugen Feist¹, Evgeny Nasonov², Michael Luggen³, Saeed Fatenejad⁴, Sergey Grishin⁵, Mikhail Samsonov⁶ and Roy Fleischmann⁷, ¹Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³University of Cincinnati College of Medicine, Cincinnati, OH, ⁴SFC Medica, LLC, Charlotte, NC, ⁵R-Pharm, Moscow, Russia, ⁶R-Pharm JSC, Moscow, Russia, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Olokizumab (OKZ), an IL-6 ligand inhibitor, demonstrated significant improvements in signs and symptoms of RA vs placebo (PL) and non-inferiority to adalimumab (ADA).1-2 Patients…
Abstract Number: 0531 • ACR Convergence 2022
Development and Performance of a Diagnostic Precision Biomarker for Seronegative Rheumatoid Arthritis Based on DNA Methylation in Blood
Espen Riskedal¹, Karl Trygve Kalleberg¹, Arne Søraas², Maria Dahl Mjaavatten³, Grethe-Elisabeth Stenvik⁴, Joe Sexton⁴, Janis Neumann¹, Cathrine Lund Hadley¹, Guro Goll⁴, Silje Watterdal Syversen⁴, Håkon Bøås⁵, Jennifer Ruth Harris⁵, Astanand Jugessur⁵, Siri Lillegraven⁴ and Espen Haavardsholm⁴, ¹Age Labs AS, Oslo, Oslo, Norway, ²Age Labs AS, Eiksmarka, Norway, ³Diakonhjemmet Hospital, Haslum, Norway, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Norwegian Institute of Public Health, Oslo, Norway
Background/Purpose: Patients with seronegative rheumatoid arthritis (RA) exhibit no detectable antibodies, often resulting in delayed diagnosis and treatment initiation. A blood-based test, capable of detecting…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].